Cantini et al., demonstrated that a chimeric peptide consisting of a fusogenic sequence, in combination with cell-penetrating residues, can be used to effectively deliver siRNAs into oral cancer cells and induce the silencing of its target gene, potentially offering a novel therapeutic strategy involving CIP2A in combating oral cancer [101]. Here, CIP2A is linked to lip and oral cavity carcinoma.